2023 World Conference on Lung Cancer (Posters)-P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer

P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer - PDF(Abstract)

Pdf Summary

This study aimed to evaluate the prognostic value of DNA ploidy and nucleotyping in early-stage non-small cell lung cancer (NSCLC) patients. The researchers also explored whether adjuvant chemotherapy benefitted patients with different nucleotyping profiles. The study included 154 early-stage NSCLC patients, and chromatin structure typing analysis was used to measure DNA ploidy, nucleotyping, and stroma-tumor fraction. <br /><br />The results showed that 66.2% of the patients were non-diploid, 26.0% had chromatin heterogeneity, and 81.8% had a low stroma fraction. Non-diploid status was associated with a lower 5-year disease-free survival rate. When combining DNA ploidy and nucleotyping for risk stratification and adjusting for confounders, the high-risk and medium-risk groups had a 4-fold and 3-fold increase in the hazard for disease progression or mortality within 5 years, compared to low-risk patients. In the high-risk group, adjuvant therapy was associated with significantly improved 5-year disease-free survival.<br /><br />The study concludes that non-diploid DNA status and the combination of ploidy and nucleotyping can be useful prognostic indicators for long-term outcomes in early-stage NSCLC patients. Additionally, NSCLC patients with chromatin heterogeneity and non-diploid DNA status might benefit from adjuvant therapy. These findings highlight the potential of using chromatin structure typing as a tool for risk stratification and personalized treatment selection in NSCLC patients.

Asset Subtitle

Luning Mao

Meta Tag

Speaker Luning Mao

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

prognostic value

DNA ploidy

nucleotyping

NSCLC

adjuvant chemotherapy

chromatin structure typing

disease-free survival

risk stratification

adjuvant therapy

chromatin heterogeneity